These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy. Hellwig K; Tokic M; Thiel S; Esters N; Spicher C; Timmesfeld N; Ciplea AI; Gold R; Langer-Gould A JAMA Netw Open; 2022 Jan; 5(1):e2144750. PubMed ID: 35072719 [TBL] [Abstract][Full Text] [Related]
4. Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. Portaccio E; Ghezzi A; Hakiki B; Sturchio A; Martinelli V; Moiola L; Patti F; Mancardi GL; Solaro C; Tola MR; Pozzilli C; De Giglio L; Totaro R; Lugaresi A; De Luca G; Paolicelli D; Marrosu MG; Comi G; Trojano M; Amato MP; J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):845-50. PubMed ID: 24403285 [TBL] [Abstract][Full Text] [Related]
5. Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. Razaz N; Piehl F; Frisell T; Langer-Gould AM; McKay KA; Fink K Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 33087582 [TBL] [Abstract][Full Text] [Related]
6. Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy. Berenguer-Ruiz L; Gimenez-Martinez J; Palazón-Bru A; Sempere AP J Neurol; 2019 Oct; 266(10):2512-2517. PubMed ID: 31256279 [TBL] [Abstract][Full Text] [Related]
7. Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria. Bsteh G; Algrang L; Hegen H; Auer M; Wurth S; Di Pauli F; Deisenhammer F; Berger T Mult Scler; 2020 Jan; 26(1):69-78. PubMed ID: 30507345 [TBL] [Abstract][Full Text] [Related]
8. Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy. Thiel S; Litvin N; Haben S; Gold R; Hellwig K J Neurol Neurosurg Psychiatry; 2024 May; 95(6):561-570. PubMed ID: 38124108 [TBL] [Abstract][Full Text] [Related]
9. Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis. Demortiere S; Rico A; Maarouf A; Boutiere C; Pelletier J; Audoin B Mult Scler; 2021 Apr; 27(5):712-718. PubMed ID: 32202216 [TBL] [Abstract][Full Text] [Related]
10. Treatment with natalizumab during pregnancy in multiple sclerosis: The experience of implementing a clinical practice protocol (NAP-30). Valero-López G; Millán-Pascual J; Iniesta-Martínez F; Delgado-Marín JL; Jimenez-Veiga J; Tejero-Martín AB; León-Hernández A; Zamarro-Parra J; Morales-Ortiz A; Meca-Lallana JE Mult Scler Relat Disord; 2022 Oct; 66():104038. PubMed ID: 35870370 [TBL] [Abstract][Full Text] [Related]
11. Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years. Portaccio E; Pastò L; Razzolini L; Moiola L; Martinelli V; Annovazzi P; Ghezzi A; Zaffaroni M; Lanzillo R; Brescia Morra V; Rinaldi F; Gallo P; Gasperini C; Paolicelli D; Simone M; Pozzilli C; De Giglio L; Cavalla P; Cocco E; Marrosu MG; Patti F; Solaro C; Comi G; Filippi M; Trojano M; Amato MP Mult Scler; 2022 Nov; 28(13):2137-2141. PubMed ID: 35296189 [TBL] [Abstract][Full Text] [Related]
12. Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis. Vukusic S; Durand-Dubief F; Benoit A; Marignier R; Frangoulis B; Confavreux C Mult Scler; 2015 Jun; 21(7):953-5. PubMed ID: 25305253 [TBL] [Abstract][Full Text] [Related]
13. Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era. Alroughani R; Alowayesh MS; Ahmed SF; Behbehani R; Al-Hashel J Neurology; 2018 Mar; 90(10):e840-e846. PubMed ID: 29429970 [TBL] [Abstract][Full Text] [Related]
14. Pregnancy and Family Planning in Multiple Sclerosis. Langer-Gould AM Continuum (Minneap Minn); 2019 Jun; 25(3):773-792. PubMed ID: 31162316 [TBL] [Abstract][Full Text] [Related]
15. Rituximab, MS, and pregnancy. Smith JB; Hellwig K; Fink K; Lyell DJ; Piehl F; Langer-Gould A Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32358226 [TBL] [Abstract][Full Text] [Related]
16. Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception. Demortiere S; Maarouf A; Rico A; Boutiere C; Hilezian F; Durozard P; Pelletier J; Audoin B Neurol Neuroimmunol Neuroinflamm; 2023 Sep; 10(5):. PubMed ID: 37550074 [TBL] [Abstract][Full Text] [Related]
17. Pregnancy outcomes amongst multiple sclerosis females with third trimester natalizumab use. Triplett JD; Vijayan S; Rajanayagam S; Tuch P; Kermode AG Mult Scler Relat Disord; 2020 May; 40():101961. PubMed ID: 32028118 [TBL] [Abstract][Full Text] [Related]
18. Risk of relapses during pregnancy among multiple sclerosis patients. Alroughani R; Akhtar S; Zeineddine M; El Kouzi Y; El Ayoubi NK; Ahmed SF; Behbehani R; Khoury SJ; Al-Hashel JY; Yamout BI Mult Scler Relat Disord; 2019 Sep; 34():9-13. PubMed ID: 31202959 [TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Ciplea AI; Langer-Gould A; de Vries A; Schaap T; Thiel S; Ringelstein M; Gold R; Hellwig K Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32327455 [TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY). Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]